Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 3131-3136

  Schreiber, Stephan A ^a,b   Russmann, Anika ^a  

^a Diabetes Practice ^*  (Germany)

^b Diabetes Practice   (Germany)

Author keywords

Clinical practice; Educational programme; Insulin glargine; NPH insulin; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

ADULT; ARTICLE; BEDTIME DOSAGE; BODY WEIGHT; CLINICAL PRACTICE; CLINICAL SUPERVISION; CONSULTATION; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFICACY; EDUCATION PROGRAM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC REGULATION; PHYSICIAN; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 37749041425     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242827     Document Type: Article

References (28)

1. Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999;15:42-6
2. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86
3. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8
4. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33
5. Pieber T, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000;23:157-62
6. Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-71
7. Heinemann L, Linkeschowa R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
8. Rosenstock J, Schwartz SL, Clark CMJ, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6
9. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6
10. Ratner RE, Hirsch IB, Neifing JL, et al Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-43
11. Schreiber SA, Russmann A. The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice. Curr Med Res Opin 2006;22:335-41
12. Schreiber SA, Russmann A. Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain. Exp Clin Endocrinol Diabetes 2006;114:41-2
13. Mollema ED, Snoek FJ, Ader HJ, et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res 2001;51:665-72
14. Berlin I, Bisserbe JC, Eiber R, et al. Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. Diabetes Care 1997;20:176-8
15. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937-48
16. Rubin R, Peyrot M, Saudek CD. Effect of diabetes education on self-care, metabolic control, and emotional well-being. Diabetes Care 1989;12:673-9
17. Langewitz W, Wossmer B, Iseli J, Berger W. Psychological and metabolic improvement after an outpatient teaching program for functional intensified insulin therapy (FIT). Diabetes Res Clin Pract 1997;37:157-64
18. Schiel R, Ulbrich S, Muller U. Quality of diabetes care, diabetes knowledge and risk of severe hypoglycaemia one and four years after participation in a 5-day structured treatment and teaching programme for intensified insulin therapy. Diabetes Metab 1998;24:509-14
19. Graziani C, Rosenthal M, Diamond J. Diabetes education program use and patient-perceived barriers to attendance. Fam Med 1999;31:358-63
20. Tankova T, Dakovska G, Koev D. Education of diabetic patients - a one year experience. Patient Educ Couns 2001;43:139-45
21. Lemonzy-Cadroy S, Crognier S, Gourdy P et al. Intensified treatment of type 1 diabetes: prospective evaluation at one year of a therapeutic patient education programme. Diabetes Metab 2002;28(4 pt 1):287-94
22. Sinha A FC, Tsalamandris C, Panagiotopoulos S, et al. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. Diabet Med 1996;13:40-6
23. DCCT. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711-21
24. Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280:140-6
25. Grimaldi A, Vialettes B, Blayo A, et al. Comparison of dinner with bedtime administration of insulin glargine in type 1 diabetic patients treated with basal-bolus regimen. Diabetes Metab 2007;33:121-8
26. Chatterjee S, Jarvis-Kay J, Rengarajan T, et al. Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes - the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract 2007;77:215-22
27. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005;21:545-53
28. Gomis R, Storms F, Conget I, Sinnassamy P, Davies M. Improving metabolic control in sub-optimally controlled subjects with type 1 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Res Clin Pract 2007;77:84-91